ATE249234T1 - Lösliches thrombomodulin enthaltende zubereitung - Google Patents
Lösliches thrombomodulin enthaltende zubereitungInfo
- Publication number
- ATE249234T1 ATE249234T1 AT95902979T AT95902979T ATE249234T1 AT E249234 T1 ATE249234 T1 AT E249234T1 AT 95902979 T AT95902979 T AT 95902979T AT 95902979 T AT95902979 T AT 95902979T AT E249234 T1 ATE249234 T1 AT E249234T1
- Authority
- AT
- Austria
- Prior art keywords
- soluble
- soluble thrombomodulin
- thrombomodulins
- preparation
- preparation containing
- Prior art date
Links
- 102000012607 Thrombomodulin Human genes 0.000 title abstract 3
- 108010079274 Thrombomodulin Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 238000001179 sorption measurement Methods 0.000 abstract 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seasonings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31840593 | 1993-12-17 | ||
| PCT/JP1994/002128 WO1995016460A1 (en) | 1993-12-17 | 1994-12-16 | Composition containing soluble thrombomodulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE249234T1 true ATE249234T1 (de) | 2003-09-15 |
Family
ID=18098790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95902979T ATE249234T1 (de) | 1993-12-17 | 1994-12-16 | Lösliches thrombomodulin enthaltende zubereitung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5834028A (de) |
| EP (1) | EP0689843B1 (de) |
| JP (1) | JP3537440B2 (de) |
| AT (1) | ATE249234T1 (de) |
| AU (1) | AU692497B2 (de) |
| CA (1) | CA2156255C (de) |
| DE (1) | DE69433133T2 (de) |
| WO (1) | WO1995016460A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| DE69837493T2 (de) | 1997-10-15 | 2007-12-13 | Asahi Kasei Pharma Corp. | Verfahren zur qualitätssicherstellung von wässrigen parenteralen lösungen mit thrombomodulin in der lagerung und verteilung |
| CA2311530C (en) * | 1998-01-30 | 2008-06-10 | Novartis Consumer Health S.A. | Nasal solutions |
| US6261820B1 (en) | 1999-10-01 | 2001-07-17 | Amgen Inc. | Fibronolytically active polypeptide |
| AU2006200638B2 (en) * | 1999-10-01 | 2007-11-01 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| AU2004201694B2 (en) * | 1999-10-01 | 2006-03-02 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| US7033776B2 (en) | 1999-12-17 | 2006-04-25 | Amgen Inc. | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases |
| EP1475098B1 (de) * | 2002-01-18 | 2015-08-05 | Asahi Kasei Pharma Corporation | Hochkonzentrierte zubereitung von löslichem thrombomodulin |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| WO2004028557A1 (ja) * | 2002-09-26 | 2004-04-08 | Shionogi & Co., Ltd. | 安定化されたタンパク組成物 |
| US7033317B2 (en) * | 2003-06-05 | 2006-04-25 | Hydrocision, Inc. | Disposable endoscope and method of making a disposable endoscope |
| US7833978B2 (en) | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| AU2006267176A1 (en) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-beta structure binding compounds |
| WO2007008073A2 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF |
| ES2360610T3 (es) * | 2005-10-13 | 2011-06-07 | Eli Lilly And Company | Tratamiento de la insuficiencia renal aguda con trombomodulina soluble. |
| CA2645930A1 (en) * | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
| CA2681294C (en) | 2007-03-23 | 2014-05-06 | Asahi Kasei Pharma Corporation | Method for producing high-purity soluble thrombomodulin |
| EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
| EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
| CA2743141A1 (en) * | 2008-11-12 | 2010-05-20 | Eli Lilly And Company | Compositions and methods of use for soluble thrombomodulin variants |
| SG10201500036WA (en) | 2010-04-30 | 2015-02-27 | Asahi Kasei Pharma Corp | Highly-purified soluble thrombomodulin and method for producing same |
| AU2014229282B2 (en) * | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| CN107987157A (zh) * | 2017-12-19 | 2018-05-04 | 江苏艾迪药业有限公司 | 一种可工业化生产的人来源血凝调节蛋白的制备方法 |
| WO2019220654A1 (ja) * | 2018-05-17 | 2019-11-21 | 旭化成ファーマ株式会社 | N-ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
| EP0816494A1 (de) * | 1987-01-08 | 1998-01-07 | Asahi Kasei Kogyo Kabushiki Kaisha | DNS kodierend für ein Peptid das die Wirkung des Proteins C mit Thrombin beschleunigt und Verfahren zu dessen Herstellung |
| JP2738428B2 (ja) * | 1987-01-08 | 1998-04-08 | 旭化成工業株式会社 | トロンビンによるプロテインcの活性化を促進する作用を有するペプチド |
| JPS6440433A (en) * | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
| US5202421A (en) * | 1988-12-27 | 1993-04-13 | Mochida Pharmaceutical Co., Ltd. | Anticoagulant substance obtained from urine and process for the preparation thereof |
| JPH0798840B2 (ja) * | 1988-12-27 | 1995-10-25 | 持田製薬株式会社 | 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物 |
| JPH02255699A (ja) * | 1989-03-28 | 1990-10-16 | Asahi Chem Ind Co Ltd | 新規血液抗凝固物質及びその製法 |
| WO1991004276A1 (en) * | 1989-09-25 | 1991-04-04 | Asahi Kasei Kogyo Kabushiki Kaisha | Isolated, physiologically active human thrombomodulin polypeptide |
| IT1240314B (it) * | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| JP3189052B2 (ja) * | 1990-06-27 | 2001-07-16 | 持田製薬株式会社 | 抗血液凝固活性を有するポリペプチド |
| JP3376591B2 (ja) * | 1991-08-28 | 2003-02-10 | 三菱ウェルファーマ株式会社 | プロテインc活性化促進剤 |
| ATE264913T1 (de) * | 1992-02-05 | 2004-05-15 | Paion Gmbh | Protease-resistente analoge des thrombomodulin |
| JP3007785B2 (ja) * | 1993-03-16 | 2000-02-07 | 旭化成工業株式会社 | トロンボモジュリン組成物およびその変性防止方法 |
-
1994
- 1994-12-16 EP EP95902979A patent/EP0689843B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69433133T patent/DE69433133T2/de not_active Expired - Lifetime
- 1994-12-16 WO PCT/JP1994/002128 patent/WO1995016460A1/ja not_active Ceased
- 1994-12-16 JP JP51667295A patent/JP3537440B2/ja not_active Expired - Fee Related
- 1994-12-16 AU AU12009/95A patent/AU692497B2/en not_active Expired
- 1994-12-16 CA CA002156255A patent/CA2156255C/en not_active Expired - Lifetime
- 1994-12-16 AT AT95902979T patent/ATE249234T1/de not_active IP Right Cessation
- 1994-12-16 US US08/505,337 patent/US5834028A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0689843B1 (de) | 2003-09-10 |
| EP0689843A1 (de) | 1996-01-03 |
| US5834028A (en) | 1998-11-10 |
| EP0689843A4 (de) | 2000-06-28 |
| DE69433133D1 (de) | 2003-10-16 |
| JP3537440B2 (ja) | 2004-06-14 |
| AU1200995A (en) | 1995-07-03 |
| CA2156255A1 (en) | 1995-06-22 |
| DE69433133T2 (de) | 2004-04-01 |
| CA2156255C (en) | 2008-02-05 |
| WO1995016460A1 (en) | 1995-06-22 |
| AU692497B2 (en) | 1998-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE249234T1 (de) | Lösliches thrombomodulin enthaltende zubereitung | |
| CA2070254A1 (en) | Thrombin inhibitors | |
| AU3496297A (en) | Anticoagulant agents | |
| AU6549394A (en) | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors | |
| ATE231496T1 (de) | Saccharinderivate als proteolytische enzyminhibitoren | |
| BG102410A (en) | Fine molecular inhibitors of rotamase enzymic activity | |
| IL113505A (en) | Factor xa inhibitors and pharmaceutical compositions containing same | |
| EP0401508A3 (de) | Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel | |
| AU5242000A (en) | Nematicidal trifluorobutenes | |
| FI925787A0 (fi) | Proteolytiska enzymers sackarinderivatinhibitorer | |
| AU5965998A (en) | Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative | |
| RU94046295A (ru) | L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава | |
| FI942625A0 (fi) | Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina | |
| AU667530B2 (en) | Removal of antibodies from blood-derived compositions while retaining coagulation factors | |
| EP0471756A4 (en) | Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof | |
| DK0410207T3 (da) | Stabilisering af højrensede proteiner. | |
| PL301576A1 (en) | Novel hiv protease inhibitors, method of obtaining such inhibitors, pharmaceutical preparation and novel initial compounds | |
| NO177312C (no) | Fremgangsmåte for fremstilling av hirudinderivater med forsinket virkning | |
| AU679581B2 (en) | Method of stabilizing protein C or activated protein C and stabilized composition | |
| WO1990003172A3 (en) | Bile acids for treatment of viral infections | |
| FI925875A7 (fi) | Menetelmä uusien proteolyyttisten entsyymien inhibiittoreina käyttökelpoisten 2-sakkarinyylimetyyli- ja 4,5,6,7-tetrahydro-2-sakkarinyylimetyylifosfaattien, -fosfonaattien ja -fosfinaattien valmistamiseksi | |
| NO911237D0 (no) | Fremgangsmaate for fremstilling av hydroxymethyl-indolizidiner og -kinolizidiner. | |
| TW290431B (de) | ||
| EP0316907A3 (en) | Enzyme inhibitor and method of producing the same | |
| HUP9603364A2 (hu) | Ipriflavont tartalmazó csonthiány pótlására szolgáló gyógyászati készítmény és eljárás előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |